Product News

AstraZeneca Pharmaceuticals responds to the chronic obstructive pulmonary disease crisis with the launch of a non-interventional study – COPVAR

Claudia Naidu


According to World Health Organization (WHO) reports, chronic
obstructive pulmonary disease (COPD) is the third-leading cause of
deaths worldwide.[1] Further, it is the sixth-leading cause of disabilityadjusted
life years (DALYs) in middle-income countries – a figure that
is expected to change to the fifth-leading cause worldwide in 2030 – and
the significance of the disease is becoming quite evident. In response to
this, AstraZeneca, a global, research-based biopharmaceutical company
with a vested interest in the development of life-changing respiratory
medications, has launched a cross-sectional study of patients with
severe COPD that assesses patient perception of symptom variability
in Middle East and African (MEA) countries.

Author's affiliations

Claudia Naidu, Health and Medical Publishing Group

Full Text:

PDF (46KB)

Cite this article

African Journal of Thoracic and Critical Care Medicine 2016;22(4):108. DOI:10.7196/SARJ.2016.v22i4.110

Article History

Date submitted: 2016-12-19
Date published: 2016-12-19

Article Views

Abstract views: 400
Full text views: 342


  • There are currently no refbacks.

African Journal of Thoracic and Critical Care Medicine| Online ISSN: 2617-0205

This journal is protected by a Creative Commons Attribution - NonCommercial Works License (CC BY-NC 4.0) | Read our privacy policy.

Our Journals: South African Medical Journal | African Journal of Health Professions Education | South African Journal of Bioethics and Law | South African Journal of Child Health | Southern African Journal of Critical Care | South African Respiratory Journal South African Journal of Obstetrics and Gynaecology |